Cargando…
Rac1, A Potential Target for Tumor Therapy
RAS-related C3 botulinum toxin substrate 1 (Rac.1) is one of the important members of Rho GTPases. It is well known that Rac1 is a cytoskeleton regulation protein that regulates cell adhesion, morphology, and movement. Rac1 is highly expressed in different types of tumors, which is related to poor p...
Autores principales: | , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8165220/ https://www.ncbi.nlm.nih.gov/pubmed/34079763 http://dx.doi.org/10.3389/fonc.2021.674426 |
_version_ | 1783701271529652224 |
---|---|
author | Liang, Jiaxin Oyang, Linda Rao, Shan Han, Yaqian Luo, Xia Yi, Pin Lin, Jinguan Xia, Longzheng Hu, Jiaqi Tan, Shiming Tang, Lu Pan, Qing Tang, Yanyan Zhou, Yujuan Liao, Qianjin |
author_facet | Liang, Jiaxin Oyang, Linda Rao, Shan Han, Yaqian Luo, Xia Yi, Pin Lin, Jinguan Xia, Longzheng Hu, Jiaqi Tan, Shiming Tang, Lu Pan, Qing Tang, Yanyan Zhou, Yujuan Liao, Qianjin |
author_sort | Liang, Jiaxin |
collection | PubMed |
description | RAS-related C3 botulinum toxin substrate 1 (Rac.1) is one of the important members of Rho GTPases. It is well known that Rac1 is a cytoskeleton regulation protein that regulates cell adhesion, morphology, and movement. Rac1 is highly expressed in different types of tumors, which is related to poor prognosis. Studies have shown that Rac1 not only participates in the tumor cell cycle, apoptosis, proliferation, invasion, migration and angiogenesis, but also participates in the regulation of tumor stem cell, thus promoting the occurrence of tumors. Rac1 also plays a key role in anti-tumor therapy and participates in immune escape mediated by the tumor microenvironment. In addition, the good prospects of Rac1 inhibitors in cancer prevention and treatment are exciting. Therefore, Rac1 is considered as a potential target for the prevention and treatment of cancer. The necessity and importance of Rac1 are obvious, but it still needs further study. |
format | Online Article Text |
id | pubmed-8165220 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-81652202021-06-01 Rac1, A Potential Target for Tumor Therapy Liang, Jiaxin Oyang, Linda Rao, Shan Han, Yaqian Luo, Xia Yi, Pin Lin, Jinguan Xia, Longzheng Hu, Jiaqi Tan, Shiming Tang, Lu Pan, Qing Tang, Yanyan Zhou, Yujuan Liao, Qianjin Front Oncol Oncology RAS-related C3 botulinum toxin substrate 1 (Rac.1) is one of the important members of Rho GTPases. It is well known that Rac1 is a cytoskeleton regulation protein that regulates cell adhesion, morphology, and movement. Rac1 is highly expressed in different types of tumors, which is related to poor prognosis. Studies have shown that Rac1 not only participates in the tumor cell cycle, apoptosis, proliferation, invasion, migration and angiogenesis, but also participates in the regulation of tumor stem cell, thus promoting the occurrence of tumors. Rac1 also plays a key role in anti-tumor therapy and participates in immune escape mediated by the tumor microenvironment. In addition, the good prospects of Rac1 inhibitors in cancer prevention and treatment are exciting. Therefore, Rac1 is considered as a potential target for the prevention and treatment of cancer. The necessity and importance of Rac1 are obvious, but it still needs further study. Frontiers Media S.A. 2021-05-17 /pmc/articles/PMC8165220/ /pubmed/34079763 http://dx.doi.org/10.3389/fonc.2021.674426 Text en Copyright © 2021 Liang, Oyang, Rao, Han, Luo, Yi, Lin, Xia, Hu, Tan, Tang, Pan, Tang, Zhou and Liao https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology Liang, Jiaxin Oyang, Linda Rao, Shan Han, Yaqian Luo, Xia Yi, Pin Lin, Jinguan Xia, Longzheng Hu, Jiaqi Tan, Shiming Tang, Lu Pan, Qing Tang, Yanyan Zhou, Yujuan Liao, Qianjin Rac1, A Potential Target for Tumor Therapy |
title | Rac1, A Potential Target for Tumor Therapy |
title_full | Rac1, A Potential Target for Tumor Therapy |
title_fullStr | Rac1, A Potential Target for Tumor Therapy |
title_full_unstemmed | Rac1, A Potential Target for Tumor Therapy |
title_short | Rac1, A Potential Target for Tumor Therapy |
title_sort | rac1, a potential target for tumor therapy |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8165220/ https://www.ncbi.nlm.nih.gov/pubmed/34079763 http://dx.doi.org/10.3389/fonc.2021.674426 |
work_keys_str_mv | AT liangjiaxin rac1apotentialtargetfortumortherapy AT oyanglinda rac1apotentialtargetfortumortherapy AT raoshan rac1apotentialtargetfortumortherapy AT hanyaqian rac1apotentialtargetfortumortherapy AT luoxia rac1apotentialtargetfortumortherapy AT yipin rac1apotentialtargetfortumortherapy AT linjinguan rac1apotentialtargetfortumortherapy AT xialongzheng rac1apotentialtargetfortumortherapy AT hujiaqi rac1apotentialtargetfortumortherapy AT tanshiming rac1apotentialtargetfortumortherapy AT tanglu rac1apotentialtargetfortumortherapy AT panqing rac1apotentialtargetfortumortherapy AT tangyanyan rac1apotentialtargetfortumortherapy AT zhouyujuan rac1apotentialtargetfortumortherapy AT liaoqianjin rac1apotentialtargetfortumortherapy |